Currently, there are 66.44M common shares owned by the public and among those 61.08M shares have been available to trade.
Insiders at the company have transacted a total of 4 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 4 of these insider trades were purchases, accounting for 405,000 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The company’s stock has a 5-day price change of 125.51% and 80.65% over the past three months. NRXP shares are trading 44.13% year to date (YTD), with the 12-month market performance down to -17.13% lower. It has a 12-month low price of $0.22 and touched a high of $1.20 over the same period. NRXP has an average intraday trading volume of 1.32 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 52.05%, 53.61%, and 68.83% respectively.
Institutional ownership of NRX Pharmaceuticals Inc (NASDAQ: NRXP) shares accounts for 4.34% of the company’s 66.44M shares outstanding.
It has a market capitalization of $60.78M and a beta (3y monthly) value of 0.98. The earnings-per-share (ttm) stands at -$0.51. Price movements for the stock have been influenced by the stock’s volatility, which stands at 21.40% over the week and 12.56% over the month.
Analysts forecast that NRX Pharmaceuticals Inc (NRXP) will achieve an EPS of -$0.07 for the current quarter, -$0.08 for the next quarter and -$0.27 for 2024. The lowest estimate earnings-per-share for the quarter is -$0.08 while analysts give the company a high EPS estimate of -$0.05. Comparatively, EPS for the current quarter was -$0.16 a year ago. Earnings per share for the fiscal year are expected to increase by 31.69%, and 34.40% over the next financial year.
